Ghaziabad Online

Soft Tissue Sarcoma (STS) with lung metastases Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

 Breaking News
  • No posts were found

Soft Tissue Sarcoma (STS) with lung metastases Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

November 16
21:21 2022
Soft Tissue Sarcoma (STS) with lung metastases Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
DelveInsight Business Research LLP
DelveInsight’s “Soft Tissue Sarcoma (STS) with lung metastases Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Soft Tissue Sarcoma (STS) with lung metastases, historical and forecasted epidemiology as well as the Soft Tissue Sarcoma (STS) with lung metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s Soft Tissue Sarcoma (STS) with lung metastases Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Soft Tissue Sarcoma (STS) with lung metastases, historical and forecasted epidemiology as well as the Soft Tissue Sarcoma (STS) with lung metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Soft Tissue Sarcoma (STS) with lung metastases market report provides current treatment practices, emerging drugs, Soft Tissue Sarcoma (STS) with lung metastases market share of the individual therapies, current and forecasted Soft Tissue Sarcoma (STS) with lung metastases market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Soft Tissue Sarcoma (STS) with lung metastases treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Soft Tissue Sarcoma (STS) with lung metastases market.

 

Click here to know more about the Soft Tissue Sarcoma (STS) with lung metastases market landscape

Some of the key facts of the Soft Tissue Sarcoma (STS) with lung metastases Market:

  • According to our analysis, there were around 42 thousand incident cases of STS in the 7MM, in 2021.

  • Among the 7MM countries, the majority of incident cases of STS were accounted in the US, in 2021.

  • In the European countries, Germany is supposed to consistently show highest incident cases of STS.

  • The incident cases of STS in Japan is expected to increase at a CAGR of 1.2% during the study period.

 

Soft Tissue Sarcoma (STS) with lung metastases Overview

The term soft tissue sarcoma (STS) refers to malignant soft-tissue tumors that may arise anywhere on the body and may consist of a variety of histological subtypes (including lipoSarcoma, rhabdomyoSarcoma, synovial Sarcoma, leiomyoSarcoma, and fibroSarcoma).

As sarcoma may arise virtually anywhere, but the extremity is the most common primary site. Despite progress in multimodality treatment, a large number of patients die each year of soft tissue sarcoma.Most STS metastasize hematogenously with the lung as main target organ. Exceptions are synovial sarcoma, clear cell sarcoma, rhabdomyosarcoma, and epithelioid sarcoma, which also spread via the lymphatic system. Primary tumors in the extremities are the most common source of pulmonary metastases, but they can originate from almost any primary site. 

Soft Tissue Sarcoma (STS) with lung metastases Epidemiology Insights

  • According to Wiltink et al. (2021), Soft tissue Sarcoma (STS) are a diverse group of rare tumors of mesenchymal origin with different clinical, histologic and molecular characteristics. 

  • American Association for Thoracic Surgery (AATS) (n.d.), stated that up to 50% of patients with soft tissue sarcoma (STS) develop lung metastasis. Also Nakamura et al. (2021), in a study mentioned that lung metastasis from STS occurs in 20–50% of STS patients.

  • According to a study by a Kawamoto et al. (2020), Pulmonary metastases develop in approximately 50% of the patients with high-grade STS, being the major cause of mortality in patients with metastatic STS. In their retrospectively review, the records of metastatic STS patients treated between 2000 and 2017 was analyzed. Out of the total patients, 61% had metastatic lesions in the bilateral lungs, and three or more lesions were found in 56% patients. 

  • Chudgar et al. (2017), reviewed a prospectively maintained database and identified patients who underwent pulmonary metastasectomy for metastatic soft-tissue sarcoma between 1991 and 2014. Of the studied cases, majority of patients (69%) presented with pulmonary metastasis only. They also mentioned that up to 50% of patients with soft tissue sarcoma develop pulmonary metastasis. 

Soft Tissue Sarcoma (STS) with lung metastases Epidemiology Segmentation

 

  • Total Soft Tissue Sarcoma (STS) with lung metastases incident cases 

  • Total Soft Tissue Sarcoma (STS) with lung metastases treatable cases 

 

Soft Tissue Sarcoma (STS) with lung metastases Market Outlook 

The Soft Tissue Sarcoma (STS) with lung metastases market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Soft Tissue Sarcoma (STS) with lung metastases market trends by analyzing the impact of current Soft Tissue Sarcoma (STS) with lung metastases therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of Soft Tissue Sarcoma (STS) with lung metastases market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Soft Tissue Sarcoma (STS) with lung metastases market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Soft Tissue Sarcoma (STS) with lung metastases market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @ Soft Tissue Sarcoma (STS) with lung metastase Market

Soft Tissue Sarcoma (STS) with lung metastases Key Companies 

  • Moleculin Biotech, Inc.
  • And others.

 

Soft Tissue Sarcoma (STS) with lung metastases Therapies

 

  • Liposomal Annamycin

  • And others

 

Table of Contents

  •  Key Insights 

  •  Report Introduction 

  •  Executive Summary of Soft Tissue Sarcoma (STS) with lung metastases 

  •  Disease Background and Overview

  •  Epidemiology and patient population

  •  The United States 

  •  EU 5

  •  Soft Tissue Sarcoma (STS) with lung metastases   Emerging Therapies

  •  Soft Tissue Sarcoma (STS) with lung metastases Market Outlook

  •  Market Access and Reimbursement of Therapies

  •  Appendix

  •  Soft Tissue Sarcoma (STS) with lung metastases Report Methodology

  •  DelveInsight Capabilities

  •  Disclaimer

Click here to read more about Soft Tissue Sarcoma (STS) with lung metastases Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/